Bartosik-Psujek Halina, Stelmasiak Zbigniew
Katedra i Klinika Neurologii, Akademia Medyczna, ul. Jaczewskiego 8, 20-954 Lublin.
Neurol Neurochir Pol. 2004;38(1 Suppl 1):S53-6.
Patients with multiple sclerosis receiving interferon beta (IFN) may develop neutralizing anti-interferon beta antibodies (NABs). The importance of NABs has not been completely explained, however it is generally reckoned that they might be one of the factors diminishing treatment efficacy. This paper presents the consequences of NABs formation during IFN therapy. Differences of immunogenicity between the interferon beta products with regard to their structure, formulation, dose, route of administration were presented and the influence of NABs on the biological and clinical activity of IFN beta therapy was shown.
接受β-干扰素（IFN）治疗的多发性硬化症患者可能会产生中和性抗β-干扰素抗体（NABs）。然而，NABs的重要性尚未完全阐明，但一般认为它们可能是降低治疗效果的因素之一。本文阐述了IFN治疗期间NABs形成的后果。介绍了不同β-干扰素产品在结构、剂型、剂量、给药途径方面的免疫原性差异，并展示了NABs对β-干扰素治疗的生物学和临床活性的影响。
